Since the start of the COVID-19 pandemic, most of the research into the SARS-CoV-2 virus has focused on its direct effects on the body with the aim of finding effective treatments and, ultimately, a cure. However, researchers Emily Severance, PhD, and Robert Yolken, MD, are investigating a potential secondary, long-term impact of COVID-19 exposure — greater susceptibility to psychosis.
“Over the years there have been data showing an association between exposure to general respiratory viruses such as the flu and subsequent psychotic episodes. This association was especially evident in studies of the aftermath of the great influenza of 1918,” Severance, assistant professor of pediatrics, Johns Hopkins University, Baltimore, Maryland, told Medscape Medical News.
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in the New England Journal of Medicine. The preliminary analysis is based on data from the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The randomized, controlled trial enrolled hospitalized adults with COVID-19 with evidence of lower respiratory tract involvement (generally moderate to severe disease). Investigators found that remdesivir was most beneficial for hospitalized patients with severe disease who required supplemental oxygen. Findings about benefits in other patient subgroups were less conclusive in this preliminary analysis.
You must be logged in to post a comment.